<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6249340</article-id><article-id pub-id-type="doi">10.3389/fphar.2018.01282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Annexins in Influenza Virus Replication and Pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ampomah</surname><given-names>Patrick Baah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/560300/overview"/></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Wan Ting</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/551893/overview"/></contrib><contrib contrib-type="author"><name><surname>Zharkova</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/638340/overview"/></contrib><contrib contrib-type="author"><name><surname>Chua</surname><given-names>Sonja C. J. H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/577210/overview"/></contrib><contrib contrib-type="author"><name><surname>Perumal Samy</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/105064/overview"/></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Lina H. K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/45211/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Physiology, NUS Immunology Program, Centre for Life Sciences, Yong Loo Lin School of Medicine, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff3"><sup>3</sup><institution>NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Shih-Min Wang, National Cheng Kung University, Taiwan</p></fn><fn fn-type="edited-by"><p>Reviewed by: Evangelos Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Greece; Ursula Rescher, Universit&#x000e4;t M&#x000fc;nster, Germany</p></fn><corresp id="c001">*Correspondence: Lina H. K. Lim, <email>linalim@nus.edu.sg</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>1282</elocation-id><history><date date-type="received"><day>04</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Ampomah, Kong, Zharkova, Chua, Perumal Samy and Lim.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Ampomah, Kong, Zharkova, Chua, Perumal Samy and Lim</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Influenza A viruses (IAVs) are important human respiratory pathogens which cause seasonal or periodic endemic infections. IAV can result in severe or fatal clinical complications including pneumonia and respiratory distress syndrome. Treatment of IAV infections is complicated because the virus can evade host immunity through antigenic drifts and antigenic shifts, to establish infections making new treatment options desirable. Annexins (ANXs) are a family of calcium and phospholipid binding proteins with immunomodulatory roles in viral infections, lung injury, and inflammation. A current understanding of the role of ANXs in modulating IAV infection and host responses will enable the future development of more effective antiviral therapies. This review presents a comprehensive understanding of the advances made in the field of ANXs, in particular, ANXA1 and IAV research and highlights the importance of ANXs as a suitable target for IAV therapy.</p></abstract><kwd-group><kwd>annexins</kwd><kwd>ANXA1</kwd><kwd>influenza virus</kwd><kwd>FPR2</kwd><kwd>immunomodulatory</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Medical Research Council<named-content content-type="fundref-id">10.13039/501100001349</named-content></funding-source><award-id rid="cn001">NMRC/CBRG/0056/2014</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="91"/><page-count count="9"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Influenza Virus</title><p>Influenza viruses (IV) are one of the most common contributors to human respiratory infections in terms of mortality and morbidity. While IV infection occurs across all age groups, individuals who are more susceptible to severe disease conditions and complications consist of infants, elderly, people with chronic diseases or are immunocompromised (<xref rid="B41" ref-type="bibr">Li et al., 2011</xref>; <xref rid="B86" ref-type="bibr">WHO, 2018</xref>). An estimate of 3&#x02013;5 million individuals suffer from severe influenza infection annually (<xref rid="B86" ref-type="bibr">WHO, 2018</xref>), with 290,000&#x02013;650,000 resulting in deaths worldwide (<xref rid="B49" ref-type="bibr">Mata et al., 2011</xref>; <xref rid="B86" ref-type="bibr">WHO, 2018</xref>). Among the four types of influenza viruses (types A, B, C, and D), Influenza A viruses (IAVs) and Influenza B viruses (IBVs) are mainly in circulation and are responsible for seasonal disease epidemics (<xref rid="B86" ref-type="bibr">WHO, 2018</xref>). Around 5% of adults and 20% of children worldwide develop symptomatic IAV or IBV each year (<xref rid="B56" ref-type="bibr">Nicholson et al., 2003</xref>). In acute infection, patients develop fevers, dry cough, sore throat, fatigue, headache, and upper respiratory tract inflammation (<xref rid="B81" ref-type="bibr">Taubenberger and Morens, 2008</xref>). IAV-related complications such as bronchitis, sinus infections, ear infections, and pneumonia may arise, which can result in organ failure and death (<xref rid="B14" ref-type="bibr">CDC, 2018</xref>). The recurrence of such seasonal influenza epidemics is primarily due to the constant mutation of the virus, reducing the effectiveness of vaccines while increasing human-human transmission (<xref rid="B66" ref-type="bibr">Petrova and Russell, 2018</xref>). Hence, the rat race between vaccine development and virus evolution makes preventive interventions and management of IAV outbreaks clinically challenging.</p></sec><sec><title>Influenza a Viral Proteins</title><p>The segmented genome encodes the hemagglutinin (HA), neuraminidase (NA), matrix protein 1, 2, and M2-related protein (M1, M2, and M42, respectively), nuclear export protein (NEP, also known as NS2), nucleoprotein (NP), non-structural protein 1 (NS1), three polymerase acid proteins (PA-X, PA-N115, and PA-N182), two polymerase basic protein 1 proteins (PB1-F2 and PB1-N40) and polymerase basic protein 2 (PB2) (<xref rid="B76" ref-type="bibr">Shaw et al., 2008</xref>; <xref rid="B53" ref-type="bibr">M&#x000fc;ller et al., 2012</xref>; <xref rid="B54" ref-type="bibr">Muramoto et al., 2013</xref>). IAV can then be further characterized according to their composition of HA and NA. Table <xref rid="T1" ref-type="table">1</xref> describes the function of the viral proteins encoded by IAV.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Influenza A viral proteins and their functions.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">RNA Segment</th><th valign="top" align="left" rowspan="1" colspan="1">Viral protein</th><th valign="top" align="left" rowspan="1" colspan="1">Function</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3</td><td valign="top" align="left" rowspan="1" colspan="1">PB1, PB2, PB1/F2, PA</td><td valign="top" align="left" rowspan="1" colspan="1">Viral polymerase proteins essential for viral RNA synthesis (<xref rid="B76" ref-type="bibr">Shaw et al., 2008</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">HA</td><td valign="top" align="left" rowspan="1" colspan="1">Recognizes and binds to host sialic acid receptor (<xref rid="B54" ref-type="bibr">Muramoto et al., 2013</xref>)<break/>Mediates fusion of viral and endosomal membrane (<xref rid="B54" ref-type="bibr">Muramoto et al., 2013</xref>)<break/>Necessary to prevent premature fusion of virus to endosome thus facilitating timely escape of viral genome into cytoplasm (<xref rid="B57" ref-type="bibr">Ning et al., 2005</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">Encapsidates viral genome (<xref rid="B28" ref-type="bibr">Fukuyama and Kawaoka, 2011</xref>)<break/>Interacts with viral polymerase proteins (<xref rid="B28" ref-type="bibr">Fukuyama and Kawaoka, 2011</xref>; <xref rid="B42" ref-type="bibr">Liedmann et al., 2014</xref>)<break/>Interacts with cellular components such as actin, import, and export machinery, etc. (<xref rid="B28" ref-type="bibr">Fukuyama and Kawaoka, 2011</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Required for budding of new viral progenies from the surface of infected cells (<xref rid="B89" ref-type="bibr">Zhang et al., 2015</xref>)<break/>Facilitates viral movement to infected cells by cleaving neuramic acid in respiratory tract mucins (<xref rid="B89" ref-type="bibr">Zhang et al., 2015</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">M1, M2</td><td valign="top" align="left" rowspan="1" colspan="1">M1 &#x02013; Provides support for virus (<xref rid="B76" ref-type="bibr">Shaw et al., 2008</xref>)<break/>M2 &#x02013; facilitates viral uncoating (<xref rid="B76" ref-type="bibr">Shaw et al., 2008</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">NS1, NS2</td><td valign="top" align="left" rowspan="1" colspan="1">NS1 &#x02013; Inhibits type I Interferon production, and type I IFN pre-mRNA processing (<xref rid="B22" ref-type="bibr">De Clercq, 2006</xref>)<break/>NS2 &#x02013; Mediates nuclear export of vRNPs (<xref rid="B77" ref-type="bibr">Shen et al., 2015</xref>)<break/>NS2 &#x02013; Regulates of viral RNA transcription (<xref rid="B77" ref-type="bibr">Shen et al., 2015</xref>)</td></tr></tbody></table></table-wrap></sec><sec><title>Iav Pathogenesis</title><p>The pathogenesis of IAV is dependent on both virus and host factors. Viral HA proteins bind to &#x003b1;2-6 sialylated glycans expressed on human epithelial cells of the upper respiratory tract to facilitate viral entry into the cell. Upon infection, the single-stranded RNA (ssRNA) of IAV is detected by pattern recognition receptors (PRRs) such as endosomal toll-like receptor 7 (TLR7) or cytosolic retinoic acid-inducible gene-I (RIG-I). This induces anti-viral host responses via a series of signaling cascade for the production of type I interferon that limits viral replication. Virus-induced transcription factors such as interferon (IFN) regulatory factor-3 (IRF-3), as well as IRF-7, serve essential roles in the expression of type-I interferons (<xref rid="B57" ref-type="bibr">Ning et al., 2005</xref>). Activated PRRs can also induce the production of pro-inflammatory mediators including IL-1, IL-6, IL-18, IL-12, TNF-&#x003b1;, and chemokines such as CCL5 (RANTES), CXCL8, CXCL10, CCL2 (MCP-1) (<xref rid="B28" ref-type="bibr">Fukuyama and Kawaoka, 2011</xref>). Macrophages recruited by these chemokines can induce apoptosis in infected alveolar epithelial cells, ultimately leading to lung inflammation and pathogenesis (<xref rid="B28" ref-type="bibr">Fukuyama and Kawaoka, 2011</xref>).</p><p>Nonetheless, IAV has evolved to overcome these innate responses. The NS1 protein is a multifunctional virulence factor that can repress activation of RIG-I, hence controlling antiviral responses by the host in the cytosol (<xref rid="B49" ref-type="bibr">Mata et al., 2011</xref>). Also, viral PB1/PA has been demonstrated to be able to suppress early IFN induction during infection (<xref rid="B42" ref-type="bibr">Liedmann et al., 2014</xref>). Nuclear NS1 also interferes with mRNA processing, affecting the proper expression of host antiviral genes (<xref rid="B28" ref-type="bibr">Fukuyama and Kawaoka, 2011</xref>). Moreover, due to the extensive genetic and antigenic diversity of IAV and the ability to undergo genetic re-assortment to infect a large host-range, there is a continuous emergence of new influenza viruses that results in periodic pandemics (<xref rid="B81" ref-type="bibr">Taubenberger and Morens, 2008</xref>).</p></sec><sec><title>Clinical Implications</title><p>At present, there are two fundamental approaches to managing the influenza epidemic: vaccination and, treatment using antivirals. Several influenza vaccines are available with several modes of administration such as forms of nasal sprays, intradermal injections, and flu jet injectors (<xref rid="B89" ref-type="bibr">Zhang et al., 2015</xref>). These vaccines often achieve up to 80% efficacy against homologous strains but become less effective in the elderly population and against heterologous IAV strains. However, the high mutability of the IAV and the sizeable antigenic diversity of viral strains emphasize the need to formulate new vaccines annually (<xref rid="B49" ref-type="bibr">Mata et al., 2011</xref>). Increasing numbers of antivirals have been approved to facilitate influenza treatment. Amantadine and rimantadine target the IAV M2 proteins, to inhibit uncoating of the virus, while oseltamivir, zanamivir, and peramivir target NA to prevent virus spread (<xref rid="B22" ref-type="bibr">De Clercq, 2006</xref>; <xref rid="B77" ref-type="bibr">Shen et al., 2015</xref>). However, the emergence of resistant virus strains has rendered M2 inhibitors useless, and there is growing resistance against NA inhibitors such as the H274Y mutation found in the 2009 H1N1 strain that made the virus oseltamivir-resistant (<xref rid="B3" ref-type="bibr">Arias et al., 2009</xref>; <xref rid="B77" ref-type="bibr">Shen et al., 2015</xref>). Newer drugs have been approved in Japan that target the viral polymerase such as favipiravir, a nucleotide analog; and baloxavir marboxil which is a cap-dependent endonuclease inhibitor (<xref rid="B36" ref-type="bibr">Koszalka et al., 2017</xref>; <xref rid="B68" ref-type="bibr">Portsmouth et al., 2017</xref>). Novel techniques such as chemical genetic approaches are also employed to identify molecules, such as naphthalimides, which antagonizes NS1 (<xref rid="B49" ref-type="bibr">Mata et al., 2011</xref>).</p><p>The high mutability and emergence of resistant strains of the virus to available drugs require a focus on host factors that play critical roles in the pathogenesis of IAV. These factors represent attractive options in the development of novel therapeutics to limit viral spread and infectivity.</p></sec><sec><title>Annexins (Anxs)</title><p>Annexins are a family of calcium or phospholipid binding molecules found mostly in eukaryotes but absent in yeasts and prokaryotes (<xref rid="B70" ref-type="bibr">Rescher and Gerke, 2004</xref>; <xref rid="B43" ref-type="bibr">Lim and Pervaiz, 2007</xref>; <xref rid="B50" ref-type="bibr">Mirsaeidi et al., 2016</xref>). They are usually located inside the cell of most eukaryotic organisms, however, some ANXs are also secreted. ANXs comprised of conserved Ca<sup>2+</sup> and membrane-binding modules with conserved four or eight repeat units of amino acids and an N-terminal domain with greatest sequence variation between families (<xref rid="B6" ref-type="bibr">Barton et al., 1991</xref>). Therefore, given its diverse Ca<sup>2+</sup>dependent roles at cellular membranes, ANXs can influence other processes such as inflammation, signaling, and proliferation (<xref rid="B56" ref-type="bibr">Nicholson et al., 2003</xref>; <xref rid="B81" ref-type="bibr">Taubenberger and Morens, 2008</xref>; <xref rid="B41" ref-type="bibr">Li et al., 2011</xref>; <xref rid="B49" ref-type="bibr">Mata et al., 2011</xref>). The variability in the N-terminal domain sequence most likely specifies the different regulatory properties of the various ANX family members <italic>in vivo</italic> (<xref rid="B30" ref-type="bibr">Gerke and Moss, 2002</xref>).</p><p>There are more than 100 ANXs identified in different species (<xref rid="B30" ref-type="bibr">Gerke and Moss, 2002</xref>). Approximately 12 of these ANXs have been identified in humans and are assigned Annexin A1&#x02013;A11, and A13 with various tissue distribution and expression (<xref rid="B50" ref-type="bibr">Mirsaeidi et al., 2016</xref>). The ability of ANXs to bind to phospholipids in cellular membranes provides a possible link for its role in viral infection especially in the regulation of endocytosis and exocytosis (<xref rid="B25" ref-type="bibr">Enrich et al., 2011</xref>). Different families of ANXs have been shown in the literature to possess various functions during influenza virus infection. ANXA1, ANXA2, ANXA5, and ANXA6 amongst others have been found to play roles in inflammation and lung injury mediated by IAV. Here, we will review the functions of these ANXs, in particular, ANXA1, in the pathogenesis of IAV infection.</p><sec><title>Annexin A1</title><p>Annexin A1 (ANXA1) also known as lipocortin-I, is a member of the annexin family of proteins formed by 346 amino acids (<xref rid="B30" ref-type="bibr">Gerke and Moss, 2002</xref>). It is a 37 kDa protein and possesses the ability to change its structural conformation upon binding to calcium cations (<xref rid="B72" ref-type="bibr">Rosengarth et al., 2001a</xref>,<xref rid="B73" ref-type="bibr">b</xref>; <xref rid="B29" ref-type="bibr">Gerke et al., 2005</xref>). The changes that occur upon a conformational change may reflect a need for interacting with potential receptors and the functions of the proteins. Blood immune cells such as monocytes and granulocytes express high levels of ANXA1 and are the largest source of cellular ANXA1 with lymphocytes possessing moderate expression levels (<xref rid="B62" ref-type="bibr">Perretti et al., 1996b</xref>; <xref rid="B58" ref-type="bibr">Oliani et al., 2002</xref>).</p><p>Interestingly, B cells and platelets do not express ANXA1 (<xref rid="B64" ref-type="bibr">Perretti and Dalli, 2009</xref>). ANXA1 may localize in the nucleus, mitochondria, cytoplasm, and on the cellular membrane depending on the stimulus, and this may partially explain the different functions ANXA1 performs under different stimuli (<xref rid="B79" ref-type="bibr">Solito et al., 2006</xref>; <xref rid="B20" ref-type="bibr">D&#x02019;Acunto et al., 2014</xref>; <xref rid="B90" ref-type="bibr">Zhao et al., 2016</xref>). It exerts its inflammatory actions by being secreted from its cellular sources albeit lacking a signaling peptide (<xref rid="B64" ref-type="bibr">Perretti and Dalli, 2009</xref>). These inflammatory actions are mediated via the G protein-coupled receptor, formyl peptide receptor (FPR) (<xref rid="B84" ref-type="bibr">Walther et al., 2000</xref>).</p></sec><sec><title>Annexin A1 Signaling</title><p>ANXA1 can act endogenously as a signaling molecule, or exogenously, by binding to the FPR1, 2, or 3. Endogenously, ANXA1 regulates MAP kinase phosphorylation (<xref rid="B1" ref-type="bibr">Alldridge and Bryant, 2003</xref>), serves as a substrate for EGF tyrosine kinase (<xref rid="B60" ref-type="bibr">Pepinsky and Sinclair, 1986</xref>) as well as protein kinases such as PKC (<xref rid="B85" ref-type="bibr">Wang and Creutz, 1992</xref>). Furthermore, ANXA1 associates with NEMO, or IKK&#x003b3;, which in turn regulates NF-&#x003ba;B (<xref rid="B9" ref-type="bibr">Bist et al., 2011</xref>). Similarly, ERK and AKT phosphorylation and NF-&#x003ba;B activity were lower in ANXA1 deficient dendritic cells (<xref rid="B34" ref-type="bibr">Huggins et al., 2009</xref>). In contrast, studies on fibroblasts have reported that ANXA1 acts as an endogenous inhibitor of MAP kinase activation through the regulation of MAP kinase phosphatase 1 (<xref rid="B88" ref-type="bibr">Yang et al., 2006</xref>). ANXA1 can also enhance TGF-&#x003b2; signaling to induce Smad2 phosphorylation, and stimulation of Smad3/4 activity (<xref rid="B23" ref-type="bibr">de Graauw et al., 2010</xref>).</p><p>The breakthrough in ANXA1 signaling exogenously was shown when ANXA1 and its derived peptide (Ac2-26) were able to reduce the transmigration of neutrophils across endothelial cell monolayers, which was blocked by an FPR antagonist (<xref rid="B84" ref-type="bibr">Walther et al., 2000</xref>). After which, several studies have demonstrated that the anti-inflammatory actions of secreted ANXA1 work via FPR1 and FPR2/ALXR (<xref rid="B80" ref-type="bibr">Sugimoto et al., 2016</xref>). These receptors can homodimerize or heterodimerize to cause different cellular responses when bound to ANXA1. For instance, ANXA1 and its peptides can activate the p38 MAPK pathway via homodimerized FPR2 receptor (<xref rid="B27" ref-type="bibr">Filep, 2013</xref>). However, stimulation of heterodimerized FPR1/FPR2 by ANXA1 peptides results in PMN apoptosis through the activation of caspase 3 (<xref rid="B27" ref-type="bibr">Filep, 2013</xref>). Notably, ANXA1, through FPR1, promotes epithelial wound repair through the activation of NADPH oxidase (NOX1) (<xref rid="B40" ref-type="bibr">Leoni et al., 2013</xref>). Further, ANXA1 activation of FPR2 results in ERK phosphorylation (<xref rid="B7" ref-type="bibr">Bena et al., 2012</xref>) and NF-&#x003ba;B activation (<xref rid="B35" ref-type="bibr">Jia et al., 2013</xref>).</p></sec><sec><title>Regulation of Inflammation by ANXA1</title><p>With the growing research around this fascinating molecule, many groups have reported the double-edged sword property of ANXA1. Inflammatory conditions can result in the cleavage of full-length ANXA1 (37 kDa) to the cleaved isoform (33 kDa) and the N terminal peptide by proteinase-3 and neutrophil elastase (<xref rid="B71" ref-type="bibr">Rescher et al., 2006</xref>; <xref rid="B83" ref-type="bibr">Vong et al., 2007</xref>), or by calpain 1 (<xref rid="B87" ref-type="bibr">Williams et al., 2010</xref>). Whereas ANXA1 mediates its function via the FPR2, the ANXA1-derived N terminal peptide can activate all three isoforms of FPR (<xref rid="B80" ref-type="bibr">Sugimoto et al., 2016</xref>). This activation might explain the differential effects elicited by the whole peptide versus the functions of different N-terminal cleaved portions of the protein which have anti-inflammatory and pro-inflammatory functions (<xref rid="B87" ref-type="bibr">Williams et al., 2010</xref>). In addition, full-length ANXA1 induces the homo-dimerization of FPR2/ALXR, which results in p38 MAPK activation (<xref rid="B19" ref-type="bibr">Cooray et al., 2013</xref>), while Ac2-26 stimulates hetero-dimerization of FPR1 and FPR2/ALXR with subsequent activation of c-Jun N-terminal kinase (JNK)-signaling, resulting in IL-10 production (<xref rid="B19" ref-type="bibr">Cooray et al., 2013</xref>). Furthermore, ANXA1 can be phosphorylated (<xref rid="B60" ref-type="bibr">Pepinsky and Sinclair, 1986</xref>; <xref rid="B85" ref-type="bibr">Wang and Creutz, 1992</xref>) and sumoylated (<xref rid="B13" ref-type="bibr">Caron et al., 2013</xref>), which further confounds its activity.</p></sec><sec><title>ANXA1 as Anti-inflammatory and Pro-resolution Molecule</title><p>ANXA1 was first discovered as a phospholipase A2 inhibitor (then known as macrocortin or renocortin) (<xref rid="B18" ref-type="bibr">Cloix et al., 1983</xref>) and is well-known for its role as an anti-inflammatory, glucocorticoid-inducible molecule (<xref rid="B63" ref-type="bibr">Perretti and D&#x02019;Acquisto, 2009</xref>). In early studies in numerous animal models of inflammation, administration of ANXA1 or its N-terminal bioactive peptides exerted anti-inflammatory, anti-pyretic, and anti-migratory effects (<xref rid="B17" ref-type="bibr">Cirino et al., 1989</xref>, <xref rid="B16" ref-type="bibr">1993</xref>; <xref rid="B26" ref-type="bibr">Errasfa and Russo-Marie, 1989</xref>; <xref rid="B21" ref-type="bibr">Davidson et al., 1991</xref>; <xref rid="B65" ref-type="bibr">Perretti et al., 1995</xref>, <xref rid="B61" ref-type="bibr">1996a</xref>; <xref rid="B90" ref-type="bibr">Zhao et al., 2016</xref>). ANXA1 administration induced leukocyte detachment from the inflamed endothelium and reduced leukocyte adhesion and transendothelial migration (<xref rid="B44" ref-type="bibr">Lim et al., 1998</xref>). In the absence of ANXA1, mice exhibited aberrant inflammation and resistance to glucocorticoids (<xref rid="B31" ref-type="bibr">Hannon et al., 2003</xref>). In addition, ANXA1 activates MAPK phosphatase-1 (MKP-1), which reduces MAP kinase activation, ultimately reducing pro-inflammatory cytokine expression (<xref rid="B88" ref-type="bibr">Yang et al., 2006</xref>). ANXA1 has also been shown to enhance apoptotic leukocyte clearance by macrophages without triggering inflammatory mediator production and its subsequent inflammatory cascade (<xref rid="B48" ref-type="bibr">Maderna et al., 2005</xref>; <xref rid="B52" ref-type="bibr">Morimoto et al., 2006</xref>). In recent years, ANXA1 is shown to redirect M1 macrophages toward anti-inflammatory M2 phenotype, decreasing the expression on inflammatory cytokines like IL-6, IL-1beta, and TNF-alpha (<xref rid="B41" ref-type="bibr">Li et al., 2011</xref>; <xref rid="B51" ref-type="bibr">Moraes et al., 2017</xref>).</p><p>Overall, the anti-inflammatory properties of ANXA1 has been reported in multiple cell types, especially in innate leukocytes like neutrophils and macrophages and highlights the importance of ANXA1 protein and its peptide in regulating host defense as well as participating in resolution of inflammation (<xref rid="B12" ref-type="bibr">Buckley et al., 2014</xref>; <xref rid="B75" ref-type="bibr">Serhan, 2014</xref>).</p></sec><sec><title>ANXA1 as a Pro-inflammatory Mediator</title><p>Conflicting reports on the role of ANXA1 in promoting inflammation have recently emerged. Dendritic cells from ANXA1<sup>-/-</sup> mice stimulated with LPS, a TLR4 agonist exhibited impaired migration, decreased maturation, and lower pro-inflammatory cytokine production which was associated with impaired NF-&#x003ba;B signaling and a reduced ability to stimulate the adaptive immune response (<xref rid="B34" ref-type="bibr">Huggins et al., 2009</xref>). Similarly, macrophages from ANXA1<sup>-/-</sup> mice stimulated with TLR3 or TLR4 agonists produced less interferon beta (IFN&#x003b2;) and interferon-stimulated genes, through an association of the C-terminus of ANXA1 with TANK-binding kinase 1, leading to IRF3 phosphorylation (<xref rid="B10" ref-type="bibr">Bist et al., 2013</xref>). As mentioned, ANXA1 phosphorylation by protein kinase C (PKC) leads to subsequent translocation of ANXA1 protein to the nucleus, resulting in pro-inflammatory cytokine release (<xref rid="B90" ref-type="bibr">Zhao et al., 2016</xref>). Cleavage of ANXA1 with calpain produced peptides of ANXA1 which promoted neutrophil recruitment, which was not observed with Ac-2-26 (<xref rid="B87" ref-type="bibr">Williams et al., 2010</xref>).</p></sec><sec><title>Annexin-A1 in Influenza a Virus Infection</title><p>It was recently reported that Annexin A1 (ANXA1) enhances IAV infection (<xref rid="B4" ref-type="bibr">Arora et al., 2016</xref>). Infection with IAV enhanced ANXA1 expression, and overexpression of ANXA1 in A549 lung epithelial cells enhanced virus replication <italic>in vitro</italic>. ANXA1<sup>-/-</sup> mice exhibited improved mortality and morbidity when infected with a lethal dose of IAV, with low viral loads in their lungs compared to their wildtype littermates. ANXA1 was found to co-localize with IAV in early and late endosomes, implying that ANXA1 facilitates endosomal trafficking of IAV (<xref rid="B4" ref-type="bibr">Arora et al., 2016</xref>). This process is important for subsequent import of vRNP into the nucleus after release from the endosome. Localization of vRNP in the nucleus is essential for transcription of viral mRNA and subsequent translation into an infective virion (<xref rid="B78" ref-type="bibr">Shi et al., 2014</xref>). ANXA1 may thus facilitate this process of nuclear vRNP accumulation, resulting in increased viral loads. Furthermore, ANXA1 enhances IAV-induced apoptosis (<xref rid="B4" ref-type="bibr">Arora et al., 2016</xref>). The role of virus-induced apoptosis in their replication is still unclear, with a study demonstrating that at the later stages of infection, IAV induces apoptosis to facilitate replication (<xref rid="B91" ref-type="bibr">Zhirnov and Klenk, 2007</xref>). Together, ANXA1 appears to have profound effects on IAV replication and pathogenesis, and presents a unique opportunity for control of IAV infection.</p></sec><sec><title>ANXA1 Receptor (FPR2) in IAV Infection</title><p>Annexin A1 serves as one of the many ligands for formyl peptide receptor 2 (FPR2) (<xref rid="B47" ref-type="bibr">Maderna et al., 2010</xref>; <xref rid="B7" ref-type="bibr">Bena et al., 2012</xref>). FPR2, also called Lipoxin A4 receptor, is a G-protein coupled receptor with plasticity in its interacting ligands mediating both a pro-inflammatory and pro-resolution effector response (<xref rid="B84" ref-type="bibr">Walther et al., 2000</xref>; <xref rid="B24" ref-type="bibr">Dufton et al., 2010</xref>; <xref rid="B19" ref-type="bibr">Cooray et al., 2013</xref>). FPR2 is expressed in intestinal epithelial cells, neutrophils, macrophages, and microglial cells (<xref rid="B11" ref-type="bibr">Bonnans et al., 2006</xref>; <xref rid="B15" ref-type="bibr">Chiang et al., 2006</xref>; <xref rid="B5" ref-type="bibr">Barnig et al., 2013</xref>). As a receptor for ANXA1, understanding its role during IAV infection is essential to develop therapeutics targeting the viral disease.</p><p>One of the earliest reports to implicate FPR2 in IAV infection demonstrated that activation of FPR2 by its ligand WKYMVm-NH2, followed by IAV infection, enhanced pathogenesis and virus replication, while inhibition of FPR2 by its antagonist WRW4, repressed viral replication (<xref rid="B82" ref-type="bibr">Tcherniuk et al., 2016</xref>). IAV incorporates ANXA1 into its envelope, suggesting that ANXA1 could potentially activate FPR2 to facilitate virus replication (Figure <xref ref-type="fig" rid="F1">1</xref>). In this context, it is plausible that secreted ANXA1 can enhance viral replication by activating FPR2, which consequently induces cellular activation of ERK (<xref rid="B67" ref-type="bibr">Pleschka et al., 2001</xref>). Blocking FPR2 signaling using its antagonist WRW4 or anti-FPR2 monoclonal antibody, results in the blockage of IAV in endosomes (<xref rid="B69" ref-type="bibr">Rahman et al., 2018</xref>). Thus, FPR2 may also contribute to viral replication by facilitating IAV endosomal export into the nucleus.</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Schematic representation of the differential roles of various ANX family members. ANXA1 promotes viral attachment and endosomal trafficking, thereby enhancing viral replication. ANXA2 incorporates into IAV envelope to convert plasminogen to plasmin, which cleaves HA to facilitate replication. Similarly, ANXA5 acts as an alternative receptor that mediates IAV entry into the cells. Together, these members of the ANX family enhance the replication of virus in infected cells. On the contrary, ANXA6 restricts virus replication by binding to the M2 protein of IAV or by creating an imbalance of cholesterol homeostasis in the late endosome, which prevent viral and endosomal membrane fusion and subsequent export of the vRNP into the nucleus.</p></caption><graphic xlink:href="fphar-09-01282-g001"/></fig><p>Recent studies have shown that IAV infection induces the upregulation of FPR2 in lungs and murine macrophages by stimulating the production of type I interferons (<xref rid="B2" ref-type="bibr">Ampomah et al., 2017</xref>). Type I interferon activates the interferon-&#x003b1;&#x003b2;-receptor and activates signal transducer and activator of transcription factor 3 (STAT3), which induces FPR2 expression. Inhibiting this FPR2 induction pathway reduced viral loads, indicating that upregulation of FPR2 may be essential for virus replication and propagation (Figure <xref ref-type="fig" rid="F2">2</xref>). ANXA1 may participate in this process by contributing to amplifying type I IFN (<xref rid="B10" ref-type="bibr">Bist et al., 2013</xref>), and hence enhancing the upregulation of FPR2.</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Schematic illustration of the ANXA1 receptor in the pathogenesis of IAV infection. Infection by IAV induces the upregulation of ANXA1 receptor, FPR2 (<xref rid="B2" ref-type="bibr">Ampomah et al., 2017</xref>). In addition, ANXA1 is incorporated into the viral envelope during budding of the virus. Increased levels of FPR2 become available for activation by ANXA1 found on viral progenies. This process activates the ERK signaling pathway and ultimately results in increased viral replication (<xref rid="B82" ref-type="bibr">Tcherniuk et al., 2016</xref>). Also, FPR2 may enhance endosomal export of vRNP into the nucleus, which enhances viral replication and propagation (<xref rid="B69" ref-type="bibr">Rahman et al., 2018</xref>).</p></caption><graphic xlink:href="fphar-09-01282-g002"/></fig><p>However, pre-treatment with resolvin D1, a pro-resolution mediator and another agonist for FPR2, reduces the pro-inflammatory effects associated with TLR3 agonist (Poly I:C) treatment in human airway epithelial cells (<xref rid="B32" ref-type="bibr">Hsiao et al., 2014</xref>). Although Poly I:C is a viral mimetic and not an actual virus, it is possible that FPR2 activation by Resolvin D1, may be useful in attenuating the inflammatory effects of IAV infection, which happens to be the detrimental side effect of flu infection.</p><p>In conclusion, it is of interest to mention that the role of FPR2 in IAV infection remains unclear. This may largely be due to its ability to bind a wide range of ligands which affect inflammation differently. The role of FPR2 in IAV can be studied in the context of enhancing inflammation or resolution. In the future, a murine knockout model will be useful in dissecting the contribution of FPR2 to viral pathogenesis, and how this can be exploited to resolve virus-induced inflammation.</p></sec></sec><sec><title>Other Anxs in Influenza Virus Infection</title><sec><title>Annexin A2</title><p>Annexin A2 (ANXA2) is another member of the family of annexins that has been reported to have roles during viral replication. The incorporation of ANXA2 into IAV particles enhance viral replication, a process facilitated by the conversion of plasminogen to plasmin (<xref rid="B39" ref-type="bibr">LeBouder et al., 2008</xref>). In addition, it was recently reported that the binding of ANXA2 to highly pathogenic H5N1 influenza virus non-structural protein 1 (NS1) enhances viral replication (<xref rid="B46" ref-type="bibr">Ma et al., 2017</xref>).</p></sec><sec><title>Annexin A5</title><p>Annexin A5 (ANXA5) was reported in 1994 as a 33 kDa protein that binds 3 different strains of influenza A and one strain of influenza B via a sialic acid-independent mechanism (<xref rid="B59" ref-type="bibr">Otto et al., 1994</xref>). It was further shown that ANXA5 aids the entry of influenza viruses into cells, by acting as an alternative receptor for virus entry (<xref rid="B59" ref-type="bibr">Otto et al., 1994</xref>; <xref rid="B33" ref-type="bibr">Huang et al., 1996</xref>). Blocking of this receptor by adding external anti-serum to cell cultures inhibited virus replication, further highlighting the importance of ANXA5-mediated virus entry in the enhancement of virus replication (<xref rid="B33" ref-type="bibr">Huang et al., 1996</xref>). Influenza A virions express host ANXA5 in its membrane, inhibiting interferon gamma signaling and promoting virus replication (<xref rid="B8" ref-type="bibr">Berri et al., 2014</xref>).</p></sec><sec><title>Annexin A6</title><p>Unlike the previously described members of the ANX family, Annexin A6 (ANXA6) is reported to negatively impact IAV replication during infection. The first evidence on the possible role of ANXA6 in influenza virus infection was its ability to interact with the viral M2 protein to repress replication. IAV M2 protein is essential in the entry and late stage of the viral lifecycle (<xref rid="B78" ref-type="bibr">Shi et al., 2014</xref>). Co-expression of a myc-tagged ANXA6 and viral M2, followed by infection provided evidence of a direct interaction between the two molecules (<xref rid="B45" ref-type="bibr">Ma et al., 2012</xref>). Moreover, overexpression of ANXA6 reduced virus propagation whereas siRNA-mediated knockdown significantly enhanced virus replication (<xref rid="B45" ref-type="bibr">Ma et al., 2012</xref>). ANXA6 may also inhibit IAV replication by increasing late endosomal cholesterol levels (<xref rid="B55" ref-type="bibr">Musiol et al., 2013</xref>). By shifting cellular cholesterol pools via ANXA6 to increase late endosomal cholesterol levels, the authors were able to show a decrease in IAV replication and propagation (<xref rid="B55" ref-type="bibr">Musiol et al., 2013</xref>). Also, available evidence suggests that the accumulation of cholesterol in the late endosome impairs IAV and endosomal membrane fusion, inhibiting the release of vRNP into the cytoplasm (<xref rid="B38" ref-type="bibr">Kuhnl et al., 2018</xref>). Taken together, this suggests that ANXA6 negatively regulates viral replication possibly by interfering with viral M2 function or affecting cellular cholesterol homeostasis.</p></sec></sec><sec><title>Conclusion</title><p>The inability of vaccines to induce broad range protection against IAV in circulation, and a possible event of a mutated virus coming into circulation makes the development of therapies that enhance host antiviral mechanisms very desirable. Over the years, considerable efforts have been spent on understanding the roles of various ANX molecules in several infectious diseases, which has been carefully reviewed (<xref rid="B37" ref-type="bibr">Kuehnl et al., 2016</xref>; <xref rid="B74" ref-type="bibr">Schloer et al., 2018</xref>). To this effect, it can be concluded that ANXs represent very important molecules that are potential targets for further development in the treatment of IAV (Figure <xref ref-type="fig" rid="F2">2</xref>). As most ANX family members function in the viral entry stage during IAV infection, a broad neutralizing antibody against the ANXA1, ANXA2, and ANXA5 appears to be a suitable option for the treatment of IAV infection in order to lessen the mortality and morbidity associated with the disease. Prevention of the entry phase of the virus infection cycle will thus prevent viral replication and the excessive inflammatory side effects associated with it.</p></sec><sec><title>Author Contributions</title><p>PA, WK, OZ, SC, RPS, and LL wrote the manuscript. LL did the final editing of the manuscript.</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was supported by a grant from the National Medical Research Council (NMRC) of Singapore (NMRC/CBRG/0056/2014) to LL.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alldridge</surname><given-names>L. C.</given-names></name><name><surname>Bryant</surname><given-names>C. E.</given-names></name></person-group> (<year>2003</year>). <article-title>Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal.</article-title>
<source><italic>Exp. Cell Res.</italic></source>
<volume>290</volume>
<fpage>93</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-4827(03)00310-0</pub-id>
<?supplied-pmid 14516791?><pub-id pub-id-type="pmid">14516791</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ampomah</surname><given-names>P. B.</given-names></name><name><surname>Moraes</surname><given-names>L. A.</given-names></name><name><surname>Lukman</surname><given-names>H. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Formyl peptide receptor 2 is regulated by RNA mimics and viruses through an IFN-beta-STAT3-dependent pathway.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>32</volume>
<fpage>1468</fpage>&#x02013;<lpage>1478</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201700584RR</pub-id>
<?supplied-pmid 29127186?><pub-id pub-id-type="pmid">29127186</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname><given-names>C. F.</given-names></name><name><surname>Escalera-Zamudio</surname><given-names>M.</given-names></name><name><surname>Soto-Del Rio Mde</surname><given-names>L. A.</given-names></name><name><surname>Cobian-Guemes</surname><given-names>G.</given-names></name><name><surname>Isa</surname><given-names>P.</given-names></name><name><surname>Lopez</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Molecular anatomy of 2009 influenza virus A (H1N1).</article-title>
<source><italic>Arch. Med. Res.</italic></source>
<volume>40</volume>
<fpage>643</fpage>&#x02013;<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1016/j.arcmed.2009.10.007</pub-id>
<?supplied-pmid 20304251?><pub-id pub-id-type="pmid">20304251</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>S.</given-names></name><name><surname>Lim</surname><given-names>W.</given-names></name><name><surname>Bist</surname><given-names>P.</given-names></name><name><surname>Perumalsamy</surname><given-names>R.</given-names></name><name><surname>Lukman</surname><given-names>H. M.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Influenza A virus enhances its propagation through the modulation of Annexin-A1 dependent endosomal trafficking and apoptosis.</article-title>
<source><italic>Cell Death Differ.</italic></source>
<volume>23</volume>
<fpage>1243</fpage>&#x02013;<lpage>1256</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2016.19</pub-id>
<?supplied-pmid 26943321?><pub-id pub-id-type="pmid">26943321</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnig</surname><given-names>C.</given-names></name><name><surname>Cernadas</surname><given-names>M.</given-names></name><name><surname>Dutile</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Perrella</surname><given-names>M. A.</given-names></name><name><surname>Kazani</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.</article-title>
<source><italic>Sci. Transl. Med.</italic></source>
<volume>5</volume>:<issue>174ra26</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3004812</pub-id>
<?supplied-pmid 23447017?><pub-id pub-id-type="pmid">23447017</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>G. J.</given-names></name><name><surname>Newman</surname><given-names>R. H.</given-names></name><name><surname>Freemont</surname><given-names>P. S.</given-names></name><name><surname>Crumpton</surname><given-names>M. J.</given-names></name></person-group> (<year>1991</year>). <article-title>Amino acid sequence analysis of the annexin super-gene family of proteins.</article-title>
<source><italic>Eur. J. Biochem.</italic></source>
<volume>198</volume>
<fpage>749</fpage>&#x02013;<lpage>760</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1991.tb16076.x</pub-id><pub-id pub-id-type="pmid">1646719</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bena</surname><given-names>S.</given-names></name><name><surname>Brancaleone</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>J. M.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>287</volume>
<fpage>24690</fpage>&#x02013;<lpage>24697</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.377101</pub-id>
<?supplied-pmid 22610094?><pub-id pub-id-type="pmid">22610094</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berri</surname><given-names>F.</given-names></name><name><surname>Haffar</surname><given-names>G.</given-names></name><name><surname>Le</surname><given-names>V. B.</given-names></name><name><surname>Sadewasser</surname><given-names>A.</given-names></name><name><surname>Paki</surname><given-names>K.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Annexin V incorporated into influenza virus particles inhibits gamma interferon signaling and promotes viral replication.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>88</volume>
<fpage>11215</fpage>&#x02013;<lpage>11228</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01405-14</pub-id>
<?supplied-pmid 25031344?><pub-id pub-id-type="pmid">25031344</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bist</surname><given-names>P.</given-names></name><name><surname>Leow</surname><given-names>S. C.</given-names></name><name><surname>Phua</surname><given-names>Q. H.</given-names></name><name><surname>Shu</surname><given-names>S.</given-names></name><name><surname>Zhuang</surname><given-names>Q.</given-names></name><name><surname>Loh</surname><given-names>W. T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-kappaB: implication in breast cancer metastasis.</article-title>
<source><italic>Oncogene</italic></source>
<volume>30</volume>
<fpage>3174</fpage>&#x02013;<lpage>3185</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2011.28</pub-id>
<?supplied-pmid 21383699?><pub-id pub-id-type="pmid">21383699</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bist</surname><given-names>P.</given-names></name><name><surname>Shu</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Arora</surname><given-names>S.</given-names></name><name><surname>Nair</surname><given-names>S.</given-names></name><name><surname>Lim</surname><given-names>J. Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Annexin-A1 regulates TLR-mediated IFN-beta production through an interaction with TANK-binding kinase 1.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>191</volume>
<fpage>4375</fpage>&#x02013;<lpage>4382</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301504</pub-id>
<?supplied-pmid 24048896?><pub-id pub-id-type="pmid">24048896</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnans</surname><given-names>C.</given-names></name><name><surname>Fukunaga</surname><given-names>K.</given-names></name><name><surname>Levy</surname><given-names>M. A.</given-names></name><name><surname>Levy</surname><given-names>B. D.</given-names></name><name><surname>Nathan</surname><given-names>C.</given-names></name><name><surname>Canny</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.</article-title>
<source><italic>Am. J. Pathol.</italic></source>
<volume>168</volume>
<fpage>1064</fpage>&#x02013;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2006.051056</pub-id>
<?supplied-pmid 16565483?><pub-id pub-id-type="pmid">16565483</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>C. D.</given-names></name><name><surname>Gilroy</surname><given-names>D. W.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Proresolving lipid mediators and mechanisms in the resolution of acute inflammation.</article-title>
<source><italic>Immunity</italic></source>
<volume>40</volume>
<fpage>315</fpage>&#x02013;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2014.02.009</pub-id>
<?supplied-pmid 24656045?><pub-id pub-id-type="pmid">24656045</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caron</surname><given-names>D.</given-names></name><name><surname>Maaroufi</surname><given-names>H.</given-names></name><name><surname>Michaud</surname><given-names>S.</given-names></name><name><surname>Tanguay</surname><given-names>R. M.</given-names></name><name><surname>Faure</surname><given-names>R. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Annexin A1 is regulated by domains cross-talk through post-translational phosphorylation and SUMOYlation.</article-title>
<source><italic>Cell. Signal.</italic></source>
<volume>25</volume>
<fpage>1962</fpage>&#x02013;<lpage>1969</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2013.05.028</pub-id>
<?supplied-pmid 23727357?><pub-id pub-id-type="pmid">23727357</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="book">CDC (<year>2018</year>). <source><italic>People at High Risk of Developing Flu&#x02013;related Complications.</italic></source>
<publisher-loc>Atlanta, GA</publisher-loc>: <publisher-name>CDC</publisher-name>.</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C. N.</given-names></name><name><surname>Dahl&#x000e9;n</surname><given-names>S. E.</given-names></name><name><surname>Drazen</surname><given-names>J. M.</given-names></name><name><surname>Hay</surname><given-names>D. W. P.</given-names></name><name><surname>Rovati</surname><given-names>G. E.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.</article-title>
<source><italic>Pharmacol. Rev.</italic></source>
<volume>58</volume>
<issue>463</issue>-487 <pub-id pub-id-type="doi">10.1124/pr.58.3.4</pub-id>
<?supplied-pmid 16968948?><pub-id pub-id-type="pmid">16968948</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirino</surname><given-names>G.</given-names></name><name><surname>Cicala</surname><given-names>C.</given-names></name><name><surname>Sorrentino</surname><given-names>L.</given-names></name><name><surname>Ciliberto</surname><given-names>G.</given-names></name><name><surname>Arpaia</surname><given-names>G.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>108</volume>
<fpage>573</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1993.tb12843.x</pub-id><pub-id pub-id-type="pmid">8467352</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirino</surname><given-names>G.</given-names></name><name><surname>Peers</surname><given-names>S. H.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name><name><surname>Browning</surname><given-names>J. L.</given-names></name><name><surname>Pepinsky</surname><given-names>R. B.</given-names></name></person-group> (<year>1989</year>). <article-title>Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>86</volume>
<fpage>3428</fpage>&#x02013;<lpage>3432</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.86.9.3428</pub-id>
<?supplied-pmid 2470103?><pub-id pub-id-type="pmid">2470103</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloix</surname><given-names>J. F.</given-names></name><name><surname>Colard</surname><given-names>O.</given-names></name><name><surname>Rothhut</surname><given-names>B.</given-names></name><name><surname>Russo-Marie</surname><given-names>F.</given-names></name></person-group> (<year>1983</year>). <article-title>Characterization and partial purification of &#x02018;renocortins&#x02019;: two polypeptides formed in renal cells causing the anti-phospholipase-like action of glucocorticoids.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>79</volume>
<fpage>313</fpage>&#x02013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1983.tb10526.x</pub-id><pub-id pub-id-type="pmid">6575852</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooray</surname><given-names>S. N.</given-names></name><name><surname>Gobbetti</surname><given-names>T.</given-names></name><name><surname>Montero-Melendez</surname><given-names>T.</given-names></name><name><surname>McArthur</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>D.</given-names></name><name><surname>Clark</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>110</volume>
<fpage>18232</fpage>&#x02013;<lpage>18237</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1308253110</pub-id>
<?supplied-pmid 24108355?><pub-id pub-id-type="pmid">24108355</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Acunto</surname><given-names>C. W.</given-names></name><name><surname>Gbelcova</surname><given-names>H.</given-names></name><name><surname>Festa</surname><given-names>M.</given-names></name><name><surname>Ruml</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>The complex understanding of Annexin A1 phosphorylation.</article-title>
<source><italic>Cell. Signal.</italic></source>
<volume>26</volume>
<fpage>173</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2013.09.020</pub-id>
<?supplied-pmid 24103589?><pub-id pub-id-type="pmid">24103589</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>J.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name><name><surname>Milton</surname><given-names>A. S.</given-names></name><name><surname>Peers</surname><given-names>S. H.</given-names></name><name><surname>Rotondo</surname><given-names>D.</given-names></name></person-group> (<year>1991</year>). <article-title>Antipyretic actions of human recombinant lipocortin-1.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>102</volume>
<fpage>7</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1991.tb12122.x</pub-id><pub-id pub-id-type="pmid">1828384</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Antiviral agents active against influenza A viruses.</article-title>
<source><italic>Nat. Rev. Drug Discov.</italic></source>
<volume>5</volume>
<fpage>1015</fpage>&#x02013;<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2175</pub-id>
<?supplied-pmid 17139286?><pub-id pub-id-type="pmid">17139286</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Graauw</surname><given-names>M.</given-names></name><name><surname>van Miltenburg</surname><given-names>M. H.</given-names></name><name><surname>Schmidt</surname><given-names>M. K.</given-names></name><name><surname>Pont</surname><given-names>C.</given-names></name><name><surname>Lalai</surname><given-names>R.</given-names></name><name><surname>Kartopawiro</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>107</volume>
<fpage>6340</fpage>&#x02013;<lpage>6345</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0913360107</pub-id>
<?supplied-pmid 20308542?><pub-id pub-id-type="pmid">20308542</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufton</surname><given-names>N.</given-names></name><name><surname>Hannon</surname><given-names>R.</given-names></name><name><surname>Brancaleone</surname><given-names>V.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Patel</surname><given-names>H. B.</given-names></name><name><surname>Gray</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Anti-Inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>184</volume>
<fpage>2611</fpage>&#x02013;<lpage>2619</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0903526</pub-id>
<?supplied-pmid 20107188?><pub-id pub-id-type="pmid">20107188</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enrich</surname><given-names>C.</given-names></name><name><surname>Rentero</surname><given-names>C.</given-names></name><name><surname>de Muga</surname><given-names>S. V.</given-names></name><name><surname>Reverter</surname><given-names>M.</given-names></name><name><surname>Mulay</surname><given-names>V.</given-names></name><name><surname>Wood</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Annexin A6-Linking Ca(2+) signaling with cholesterol transport.</article-title>
<source><italic>Biochim. Biophys. Acta</italic></source>
<volume>1813</volume>
<fpage>935</fpage>&#x02013;<lpage>947</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2010.09.015</pub-id>
<?supplied-pmid 20888375?><pub-id pub-id-type="pmid">20888375</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errasfa</surname><given-names>M.</given-names></name><name><surname>Russo-Marie</surname><given-names>F.</given-names></name></person-group> (<year>1989</year>). <article-title>A purified lipocortin shares the anti-inflammatory effect of glucocorticosteroids in vivo in mice.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>97</volume>
<fpage>1051</fpage>&#x02013;<lpage>1058</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1989.tb12561.x</pub-id>
<?supplied-pmid 2529014?><pub-id pub-id-type="pmid">2529014</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filep</surname><given-names>J. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Biasing the lipoxin A4/formyl peptide receptor 2 pushes inflammatory resolution.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>110</volume>
<fpage>18033</fpage>&#x02013;<lpage>18034</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1317798110</pub-id>
<?supplied-pmid 24154723?><pub-id pub-id-type="pmid">24154723</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuyama</surname><given-names>S.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>The pathogenesis of influenza virus infections: the contributions of virus and host factors.</article-title>
<source><italic>Curr. Opin. Immunol.</italic></source>
<volume>23</volume>
<fpage>481</fpage>&#x02013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2011.07.016</pub-id>
<?supplied-pmid 21840185?><pub-id pub-id-type="pmid">21840185</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Creutz</surname><given-names>C. E.</given-names></name><name><surname>Moss</surname><given-names>S. E.</given-names></name></person-group> (<year>2005</year>). <article-title>Annexins: linking Ca<sup>2+</sup> signalling to membrane dynamics.</article-title>
<source><italic>Nat. Rev. Mol. Cell Biol.</italic></source>
<volume>6</volume>
<fpage>449</fpage>&#x02013;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1038/nrm1661</pub-id>
<?supplied-pmid 15928709?><pub-id pub-id-type="pmid">15928709</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Moss</surname><given-names>S. E.</given-names></name></person-group> (<year>2002</year>). <article-title>Annexins: from structure to function.</article-title>
<source><italic>Physiol. Rev.</italic></source>
<volume>82</volume>
<fpage>331</fpage>&#x02013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00030.2001</pub-id>
<?supplied-pmid 11917092?><pub-id pub-id-type="pmid">11917092</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannon</surname><given-names>R.</given-names></name><name><surname>Croxtall</surname><given-names>J. D.</given-names></name><name><surname>Getting</surname><given-names>S. J.</given-names></name><name><surname>Roviezzo</surname><given-names>F.</given-names></name><name><surname>Yona</surname><given-names>S.</given-names></name><name><surname>Paul-Clark</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>17</volume>
<fpage>253</fpage>&#x02013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1096/fj.02-0239fje</pub-id>
<?supplied-pmid 12475898?><pub-id pub-id-type="pmid">12475898</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>H. M.</given-names></name><name><surname>Thatcher</surname><given-names>T. H.</given-names></name><name><surname>Levy</surname><given-names>E. P.</given-names></name><name><surname>Fulton</surname><given-names>R. A.</given-names></name><name><surname>Owens</surname><given-names>K. M.</given-names></name><name><surname>Phipps</surname><given-names>R. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Resolvin D1 attenuates polyinosinic-polycytidylic acid-induced inflammatory signaling in human airway epithelial cells via TAK1.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>193</volume>
<fpage>4980</fpage>&#x02013;<lpage>4987</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1400313</pub-id>
<?supplied-pmid 25320283?><pub-id pub-id-type="pmid">25320283</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R. T.</given-names></name><name><surname>Lichtenberg</surname><given-names>B.</given-names></name><name><surname>Rick</surname><given-names>O.</given-names></name></person-group> (<year>1996</year>). <article-title>Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection.</article-title>
<source><italic>FEBS Lett.</italic></source>
<volume>392</volume>
<fpage>59</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/0014-5793(96)00783-1</pub-id>
<?supplied-pmid 8769315?><pub-id pub-id-type="pmid">8769315</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggins</surname><given-names>A.</given-names></name><name><surname>Paschalidis</surname><given-names>N.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>23</volume>
<fpage>985</fpage>&#x02013;<lpage>996</lpage>. <pub-id pub-id-type="doi">10.1096/fj.08-119040</pub-id>
<?supplied-pmid 19029200?><pub-id pub-id-type="pmid">19029200</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Morand</surname><given-names>E. F.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Cheng</surname><given-names>Q.</given-names></name><name><surname>Stewart</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>Y. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Regulation of lung fibroblast activation by annexin A1.</article-title>
<source><italic>J. Cell. Physiol.</italic></source>
<volume>228</volume>
<fpage>476</fpage>&#x02013;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.24156</pub-id>
<?supplied-pmid 22777765?><pub-id pub-id-type="pmid">22777765</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koszalka</surname><given-names>P.</given-names></name><name><surname>Tilmanis</surname><given-names>D.</given-names></name><name><surname>Hurt</surname><given-names>A. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Influenza antivirals currently in late-phase clinical trial.</article-title>
<source><italic>Influenza Other Respir. Viruses</italic></source>
<volume>11</volume>
<fpage>240</fpage>&#x02013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12446</pub-id>
<?supplied-pmid 28146320?><pub-id pub-id-type="pmid">28146320</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehnl</surname><given-names>A.</given-names></name><name><surname>Musiol</surname><given-names>A.</given-names></name><name><surname>Raabe</surname><given-names>C. A.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group> (<year>2016</year>). <article-title>Emerging functions as host cell factors - an encyclopedia of annexin-pathogen interactions.</article-title>
<source><italic>Biol. Chem.</italic></source>
<volume>397</volume>
<fpage>949</fpage>&#x02013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2016-0183</pub-id>
<?supplied-pmid 27366904?><pub-id pub-id-type="pmid">27366904</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhnl</surname><given-names>A.</given-names></name><name><surname>Musiol</surname><given-names>A.</given-names></name><name><surname>Heitzig</surname><given-names>N.</given-names></name><name><surname>Johnson</surname><given-names>D. E.</given-names></name><name><surname>Ehrhardt</surname><given-names>C.</given-names></name><name><surname>Grewal</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Late endosomal/lysosomal cholesterol accumulation is a host cell-protective mechanism inhibiting endosomal escape of influenza a virus.</article-title>
<source><italic>mBio</italic></source>
<volume>9</volume>:<issue>e1345</issue>-18. <pub-id pub-id-type="doi">10.1128/mBio.01345-18</pub-id>
<?supplied-pmid 30042202?><pub-id pub-id-type="pmid">30042202</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBouder</surname><given-names>F.</given-names></name><name><surname>Morello</surname><given-names>E.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G. F.</given-names></name><name><surname>Bosse</surname><given-names>F.</given-names></name><name><surname>Pechoux</surname><given-names>C.</given-names></name><name><surname>Delmas</surname><given-names>B.</given-names></name></person-group> (<year>2008</year>). <article-title>Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>82</volume>
<fpage>6820</fpage>&#x02013;<lpage>6828</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00246-08</pub-id>
<?supplied-pmid 18448517?><pub-id pub-id-type="pmid">18448517</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leoni</surname><given-names>G.</given-names></name><name><surname>Alam</surname><given-names>A.</given-names></name><name><surname>Neumann</surname><given-names>P. A.</given-names></name><name><surname>Lambeth</surname><given-names>J. D.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name><name><surname>McCoy</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>123</volume>
<fpage>443</fpage>&#x02013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1172/JCI65831</pub-id>
<?supplied-pmid 23241962?><pub-id pub-id-type="pmid">23241962</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2.</article-title>
<source><italic>Oncogene</italic></source>
<volume>30</volume>
<fpage>3887</fpage>&#x02013;<lpage>3899</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2011.112</pub-id>
<?supplied-pmid 21499310?><pub-id pub-id-type="pmid">21499310</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedmann</surname><given-names>S.</given-names></name><name><surname>Hrincius</surname><given-names>E. R.</given-names></name><name><surname>Guy</surname><given-names>C.</given-names></name><name><surname>Anhlan</surname><given-names>D.</given-names></name><name><surname>Dierkes</surname><given-names>R.</given-names></name><name><surname>Carter</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Viral suppressors of the RIG-I-mediated interferon response are pre-packaged in influenza virions.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>5</volume>:<issue>5645</issue>. <pub-id pub-id-type="doi">10.1038/ncomms6645</pub-id>
<?supplied-pmid 25487526?><pub-id pub-id-type="pmid">25487526</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>L. H.</given-names></name><name><surname>Pervaiz</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Annexin 1: the new face of an old molecule.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>21</volume>
<fpage>968</fpage>&#x02013;<lpage>975</lpage>. <pub-id pub-id-type="doi">10.1096/fj.06-7464rev</pub-id>
<?supplied-pmid 17215481?><pub-id pub-id-type="pmid">17215481</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>L. H.</given-names></name><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Russo-Marie</surname><given-names>F.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group> (<year>1998</year>). <article-title>Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>95</volume>
<fpage>14535</fpage>&#x02013;<lpage>14539</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.24.14535</pub-id>
<?supplied-pmid 9826735?><pub-id pub-id-type="pmid">9826735</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Maniere</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lagarde</surname><given-names>N.</given-names></name><name><surname>Tse</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Human annexin A6 interacts with influenza a virus protein M2 and negatively modulates infection.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>86</volume>
<fpage>1789</fpage>&#x02013;<lpage>1801</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06003-11</pub-id>
<?supplied-pmid 22114333?><pub-id pub-id-type="pmid">22114333</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Bao</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Annexin A2 (ANXA2) interacts with nonstructural protein 1 and promotes the replication of highly pathogenic H5N1 avian influenza virus.</article-title>
<source><italic>BMC Microbiol.</italic></source>
<volume>17</volume>:<issue>191</issue>. <pub-id pub-id-type="doi">10.1186/s12866-017-1097-0</pub-id>
<?supplied-pmid 28893180?><pub-id pub-id-type="pmid">28893180</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maderna</surname><given-names>P.</given-names></name><name><surname>Cottell</surname><given-names>D. C.</given-names></name><name><surname>Toivonen</surname><given-names>T.</given-names></name><name><surname>Dufton</surname><given-names>N.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>24</volume>
<fpage>4240</fpage>&#x02013;<lpage>4249</lpage>. <pub-id pub-id-type="doi">10.1096/fj.10-159913</pub-id>
<?supplied-pmid 20570963?><pub-id pub-id-type="pmid">20570963</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maderna</surname><given-names>P.</given-names></name><name><surname>Yona</surname><given-names>S.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Godson</surname><given-names>C.</given-names></name></person-group> (<year>2005</year>). <article-title>Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26).</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>174</volume>
<fpage>3727</fpage>&#x02013;<lpage>3733</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.174.6.3727</pub-id>
<?supplied-pmid 15749912?><pub-id pub-id-type="pmid">15749912</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mata</surname><given-names>M. A.</given-names></name><name><surname>Satterly</surname><given-names>N.</given-names></name><name><surname>Versteeg</surname><given-names>G. A.</given-names></name><name><surname>Frantz</surname><given-names>D.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Williams</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor.</article-title>
<source><italic>Nat. Chem. Biol.</italic></source>
<volume>7</volume>
<fpage>712</fpage>&#x02013;<lpage>719</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.645</pub-id>
<?supplied-pmid 21909097?><pub-id pub-id-type="pmid">21909097</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirsaeidi</surname><given-names>M.</given-names></name><name><surname>Gidfar</surname><given-names>S.</given-names></name><name><surname>Vu</surname><given-names>A.</given-names></name><name><surname>Schraufnagel</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis.</article-title>
<source><italic>J. Transl. Med.</italic></source>
<volume>14</volume>:<issue>89</issue>. <pub-id pub-id-type="doi">10.1186/s12967-016-0843-7</pub-id>
<?supplied-pmid 27071553?><pub-id pub-id-type="pmid">27071553</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraes</surname><given-names>L. A.</given-names></name><name><surname>Kar</surname><given-names>S.</given-names></name><name><surname>Foo</surname><given-names>S. L.</given-names></name><name><surname>Gu</surname><given-names>T.</given-names></name><name><surname>Toh</surname><given-names>Y. Q.</given-names></name><name><surname>Ampomah</surname><given-names>P. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>7</volume>:<issue>17925</issue>. <pub-id pub-id-type="doi">10.1038/s41598-017-17622-5</pub-id>
<?supplied-pmid 29263330?><pub-id pub-id-type="pmid">29263330</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>K.</given-names></name><name><surname>Janssen</surname><given-names>W. J.</given-names></name><name><surname>Fessler</surname><given-names>M. B.</given-names></name><name><surname>McPhillips</surname><given-names>K. A.</given-names></name><name><surname>Borges</surname><given-names>V. M.</given-names></name><name><surname>Bowler</surname><given-names>R. P.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>176</volume>
<fpage>7657</fpage>&#x02013;<lpage>7665</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.176.12.7657</pub-id>
<?supplied-pmid 16751413?><pub-id pub-id-type="pmid">16751413</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>K. H.</given-names></name><name><surname>Kakkola</surname><given-names>L.</given-names></name><name><surname>Nagaraj</surname><given-names>A. S.</given-names></name><name><surname>Cheltsov</surname><given-names>A. V.</given-names></name><name><surname>Anastasina</surname><given-names>M.</given-names></name><name><surname>Kainov</surname><given-names>D. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Emerging cellular targets for influenza antiviral agents.</article-title>
<source><italic>Trends Pharmacol. Sci.</italic></source>
<volume>33</volume>
<fpage>89</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2011.10.004</pub-id>
<?supplied-pmid 22196854?><pub-id pub-id-type="pmid">22196854</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramoto</surname><given-names>Y.</given-names></name><name><surname>Noda</surname><given-names>T.</given-names></name><name><surname>Kawakami</surname><given-names>E.</given-names></name><name><surname>Akkina</surname><given-names>R.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Identification of novel influenza A virus proteins translated from PA mRNA.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>87</volume>
<fpage>2455</fpage>&#x02013;<lpage>2462</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02656-12</pub-id>
<?supplied-pmid 23236060?><pub-id pub-id-type="pmid">23236060</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musiol</surname><given-names>A.</given-names></name><name><surname>Gran</surname><given-names>S.</given-names></name><name><surname>Ehrhardt</surname><given-names>C.</given-names></name><name><surname>Ludwig</surname><given-names>S.</given-names></name><name><surname>Grewal</surname><given-names>T.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation.</article-title>
<source><italic>mBio</italic></source>
<volume>4</volume>:<issue>e00608</issue>-13. <pub-id pub-id-type="doi">10.1128/mBio.00608-13</pub-id>
<?supplied-pmid 24194536?><pub-id pub-id-type="pmid">24194536</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>K. G.</given-names></name><name><surname>Wood</surname><given-names>J. M.</given-names></name><name><surname>Zambon</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Influenza.</article-title>
<source><italic>Lancet</italic></source>
<volume>362</volume>
<fpage>1733</fpage>&#x02013;<lpage>1745</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)14854-4</pub-id><pub-id pub-id-type="pmid">14643124</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>S.</given-names></name><name><surname>Huye</surname><given-names>L. E.</given-names></name><name><surname>Pagano</surname><given-names>J. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>280</volume>
<fpage>12262</fpage>&#x02013;<lpage>12270</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M404260200</pub-id>
<?supplied-pmid 15664995?><pub-id pub-id-type="pmid">15664995</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliani</surname><given-names>S. M.</given-names></name><name><surname>Damazo</surname><given-names>A. S.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>). <article-title>Annexin 1 localisation in tissue eosinophils as detected by electron microscopy.</article-title>
<source><italic>Mediators Inflamm.</italic></source>
<volume>11</volume>
<fpage>287</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1080/09629350210000015683</pub-id>
<?supplied-pmid 12467520?><pub-id pub-id-type="pmid">12467520</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>M.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>A.</given-names></name><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Rick</surname><given-names>O.</given-names></name><name><surname>Huang</surname><given-names>R. T.</given-names></name></person-group> (<year>1994</year>). <article-title>Identification of annexin 33 kDa in cultured cells as a binding protein of influenza viruses.</article-title>
<source><italic>FEBS Lett.</italic></source>
<volume>356</volume>
<fpage>125</fpage>&#x02013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/0014-5793(94)01241-5</pub-id>
<?supplied-pmid 7988705?><pub-id pub-id-type="pmid">7988705</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepinsky</surname><given-names>R. B.</given-names></name><name><surname>Sinclair</surname><given-names>L. K.</given-names></name></person-group> (<year>1986</year>). <article-title>Epidermal growth factor-dependent phosphorylation of lipocortin.</article-title>
<source><italic>Nature</italic></source>
<volume>321</volume>
<fpage>81</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/321081a0</pub-id>
<?supplied-pmid 3010133?><pub-id pub-id-type="pmid">3010133</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Ahluwalia</surname><given-names>A.</given-names></name><name><surname>Harris</surname><given-names>J. G.</given-names></name><name><surname>Harris</surname><given-names>H. J.</given-names></name><name><surname>Wheller</surname><given-names>S. K.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name></person-group> (<year>1996a</year>). <article-title>Acute inflammatory response in the mouse: exacerbation by immunoneutralization of lipocortin 1.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>117</volume>
<fpage>1145</fpage>&#x02013;<lpage>1154</lpage>. <?supplied-pmid 8882609?><pub-id pub-id-type="pmid">8882609</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Croxtall</surname><given-names>J. D.</given-names></name><name><surname>Wheller</surname><given-names>S. K.</given-names></name><name><surname>Goulding</surname><given-names>N. J.</given-names></name><name><surname>Hannon</surname><given-names>R.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name></person-group> (<year>1996b</year>). <article-title>Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>2</volume>
<fpage>1259</fpage>&#x02013;<lpage>1262</lpage>. <?supplied-pmid 8898757?><pub-id pub-id-type="pmid">8898757</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.</article-title>
<source><italic>Nat. Rev. Immun.</italic></source>
<volume>9</volume>
<fpage>62</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/nri2470</pub-id>
<?supplied-pmid 19104500?><pub-id pub-id-type="pmid">19104500</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>158</volume>
<fpage>936</fpage>&#x02013;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00483.x</pub-id>
<?supplied-pmid 19845684?><pub-id pub-id-type="pmid">19845684</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Wheller</surname><given-names>S. K.</given-names></name><name><surname>Choudhury</surname><given-names>Q.</given-names></name><name><surname>Croxtall</surname><given-names>J. D.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name></person-group> (<year>1995</year>). <article-title>Selective inhibition of neutrophil function by a peptide derived from lipocortin 1 N-terminus.</article-title>
<source><italic>Biochem. Pharmacol.</italic></source>
<volume>50</volume>
<fpage>1037</fpage>&#x02013;<lpage>1042</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(95)00238-U</pub-id>
<?supplied-pmid 7575659?><pub-id pub-id-type="pmid">7575659</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>V. N.</given-names></name><name><surname>Russell</surname><given-names>C. A.</given-names></name></person-group> (<year>2018</year>). <article-title>The evolution of seasonal influenza viruses.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>16</volume>
<fpage>47</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2017.146</pub-id>
<?supplied-pmid 29109554?><pub-id pub-id-type="pmid">29081496</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleschka</surname><given-names>S.</given-names></name><name><surname>Wolff</surname><given-names>T.</given-names></name><name><surname>Ehrhardt</surname><given-names>C.</given-names></name><name><surname>Hobom</surname><given-names>G.</given-names></name><name><surname>Planz</surname><given-names>O.</given-names></name><name><surname>Rapp</surname><given-names>U. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade.</article-title>
<source><italic>Nat. Cell Biol.</italic></source>
<volume>3</volume>
<fpage>301</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1038/35060098</pub-id>
<?supplied-pmid 11231581?><pub-id pub-id-type="pmid">11231581</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portsmouth</surname><given-names>S.</given-names></name><name><surname>Kawaguchi</surname><given-names>K.</given-names></name><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Tsuchiya</surname><given-names>K.</given-names></name><name><surname>Uehara</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>Cap-Dependent endonuclease inhibitor s-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza.</article-title>
<source><italic>Open Forum Infect. Dis.</italic></source> 4(Suppl. 1):S734. <pub-id pub-id-type="doi">10.1093/ofid/ofx180.001</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>F.</given-names></name><name><surname>Chebbo</surname><given-names>M.</given-names></name><name><surname>Courtin</surname><given-names>N.</given-names></name><name><surname>Fotso</surname><given-names>A.</given-names></name><name><surname>Fotso</surname><given-names>M.</given-names></name><name><surname>Alessi</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The Annexin A1 receptor FPR2 regulates the endosomal export of influenza virus.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>19</volume>:<issue>E1400</issue>. <pub-id pub-id-type="doi">10.3390/ijms19051400</pub-id>
<?supplied-pmid 29738458?><pub-id pub-id-type="pmid">29738458</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group> (<year>2004</year>). <article-title>Annexins&#x02013;unique membrane binding proteins with diverse functions.</article-title>
<source><italic>J. Cell Sci.</italic></source> 117(Pt 13), <fpage>2631</fpage>&#x02013;<lpage>2639</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.01245</pub-id>
<?supplied-pmid 15169834?><pub-id pub-id-type="pmid">15169834</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Goebeler</surname><given-names>V.</given-names></name><name><surname>Wilbers</surname><given-names>A.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group> (<year>2006</year>). <article-title>Proteolytic cleavage of annexin 1 by human leukocyte elastase.</article-title>
<source><italic>Biochim. Biophys. Acta</italic></source>
<volume>1763</volume>
<fpage>1320</fpage>&#x02013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.08.041</pub-id>
<?supplied-pmid 17023068?><pub-id pub-id-type="pmid">17023068</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosengarth</surname><given-names>A.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Luecke</surname><given-names>H.</given-names></name></person-group> (<year>2001a</year>). <article-title>X-ray structure of full-length annexin 1 and implications for membrane aggregation.</article-title>
<source><italic>J. Mol. Biol.</italic></source>
<volume>306</volume>
<fpage>489</fpage>&#x02013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.2000.4423</pub-id>
<?supplied-pmid 11178908?><pub-id pub-id-type="pmid">11178908</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosengarth</surname><given-names>A.</given-names></name><name><surname>Rosgen</surname><given-names>J.</given-names></name><name><surname>Hinz</surname><given-names>H. J.</given-names></name></person-group> (<year>2001b</year>). <article-title>Folding energetics of ligand binding proteins II. Cooperative, binding of Ca<sup>2+</sup> to annexin I.</article-title>
<source><italic>J. Mol. Biol.</italic></source>
<volume>306</volume>
<fpage>825</fpage>&#x02013;<lpage>835</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.2000.4358</pub-id>
<?supplied-pmid 11243791?><pub-id pub-id-type="pmid">11243791</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schloer</surname><given-names>S.</given-names></name><name><surname>Pajonczyk</surname><given-names>D.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group> (<year>2018</year>). <article-title>Annexins in translational research: hidden treasures to be found.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>19</volume>:<issue>1781</issue>. <pub-id pub-id-type="doi">10.3390/ijms19061781</pub-id>
<?supplied-pmid 29914106?><pub-id pub-id-type="pmid">29914106</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Pro-resolving lipid mediators are leads for resolution physiology.</article-title>
<source><italic>Nature</italic></source>
<volume>510</volume>
<fpage>92</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1038/nature13479</pub-id>
<?supplied-pmid 24899309?><pub-id pub-id-type="pmid">24899309</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>M. L.</given-names></name><name><surname>Stone</surname><given-names>K. L.</given-names></name><name><surname>Colangelo</surname><given-names>C. M.</given-names></name><name><surname>Gulcicek</surname><given-names>E. E.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Cellular proteins in influenza virus particles.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>4</volume>:<issue>e1000085</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000085</pub-id>
<?supplied-pmid 18535660?><pub-id pub-id-type="pmid">18535660</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z.</given-names></name><name><surname>Lou</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group> (<year>2015</year>). <article-title>New small-molecule drug design strategies for fighting resistant influenza A.</article-title>
<source><italic>Acta Pharm. Sin. B</italic></source>
<volume>5</volume>
<fpage>419</fpage>&#x02013;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2015.07.006</pub-id>
<?supplied-pmid 26579472?><pub-id pub-id-type="pmid">26579472</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Enabling the &#x02018;host jump&#x02019;: structural determinants of receptor-binding specificity in influenza A viruses.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>12</volume>
<fpage>822</fpage>&#x02013;<lpage>831</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3362</pub-id>
<?supplied-pmid 25383601?><pub-id pub-id-type="pmid">25383601</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Christian</surname><given-names>H. C.</given-names></name><name><surname>Festa</surname><given-names>M.</given-names></name><name><surname>Mulla</surname><given-names>A.</given-names></name><name><surname>Tierney</surname><given-names>T.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surface.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>20</volume>
<fpage>1498</fpage>&#x02013;<lpage>1500</lpage>. <pub-id pub-id-type="doi">10.1096/fj.05-5319fje</pub-id>
<?supplied-pmid 16720734?><pub-id pub-id-type="pmid">16720734</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>M. A.</given-names></name><name><surname>Vago</surname><given-names>J. P.</given-names></name><name><surname>Teixeira</surname><given-names>M. M.</given-names></name><name><surname>Sousa</surname><given-names>L. P.</given-names></name></person-group> (<year>2016</year>). <article-title>Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, Apoptosis, and Clearance.</article-title>
<source><italic>J. Immunol. Res.</italic></source>
<volume>2016</volume>
<issue>8239258</issue>. <pub-id pub-id-type="doi">10.1155/2016/8239258</pub-id>
<?supplied-pmid 26885535?><pub-id pub-id-type="pmid">26885535</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taubenberger</surname><given-names>J. K.</given-names></name><name><surname>Morens</surname><given-names>D. M.</given-names></name></person-group> (<year>2008</year>). <article-title>The pathology of influenza virus infections.</article-title>
<source><italic>Annu. Rev. Pathol.</italic></source>
<volume>3</volume>
<fpage>499</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pathmechdis.3.121806.154316</pub-id><pub-id pub-id-type="pmid">18039138</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tcherniuk</surname><given-names>S.</given-names></name><name><surname>Cenac</surname><given-names>N.</given-names></name><name><surname>Comte</surname><given-names>M.</given-names></name><name><surname>Frouard</surname><given-names>J.</given-names></name><name><surname>Errazuriz-cerda</surname><given-names>E.</given-names></name><name><surname>Galabov</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Formyl peptide receptor 2 plays a deleterious role during in fl uenza a virus infections.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>214</volume>
<fpage>237</fpage>&#x02013;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw127</pub-id>
<?supplied-pmid 27034344?><pub-id pub-id-type="pmid">27034344</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vong</surname><given-names>L.</given-names></name><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name><name><surname>Pederzoli-Ribeil</surname><given-names>M.</given-names></name><name><surname>Lavagno</surname><given-names>L.</given-names></name><name><surname>Flower</surname><given-names>R. J.</given-names></name><name><surname>Witko-Sarsat</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>282</volume>
<fpage>29998</fpage>&#x02013;<lpage>30004</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M702876200</pub-id>
<?supplied-pmid 17681950?><pub-id pub-id-type="pmid">17681950</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>A.</given-names></name><name><surname>Riehemann</surname><given-names>K.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group> (<year>2000</year>). <article-title>A novel ligand of the formyl peptide receptor.</article-title>
<source><italic>Mol. Cell</italic></source>
<volume>5</volume>
<fpage>831</fpage>&#x02013;<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1016/S1097-2765(00)80323-8</pub-id><pub-id pub-id-type="pmid">10882119</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Creutz</surname><given-names>C. E.</given-names></name></person-group> (<year>1992</year>). <article-title>Regulation of the chromaffin granule aggregating activity of annexin I by phosphorylation.</article-title>
<source><italic>Biochemistry</italic></source>
<volume>31</volume>
<fpage>9934</fpage>&#x02013;<lpage>9939</lpage>. <pub-id pub-id-type="doi">10.1021/bi00156a011</pub-id>
<?supplied-pmid 1390776?><pub-id pub-id-type="pmid">1390776</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="book">WHO (<year>2018</year>). <source><italic>Influenza (Seasonal).</italic></source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>S. L.</given-names></name><name><surname>Milne</surname><given-names>I. R.</given-names></name><name><surname>Bagley</surname><given-names>C. J.</given-names></name><name><surname>Gamble</surname><given-names>J. R.</given-names></name><name><surname>Vadas</surname><given-names>M. A.</given-names></name><name><surname>Pitson</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>A proinflammatory role for proteolytically cleaved annexin A1 in neutrophil transendothelial migration.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>185</volume>
<fpage>3057</fpage>&#x02013;<lpage>3063</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1000119</pub-id>
<?supplied-pmid 20679535?><pub-id pub-id-type="pmid">20679535</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y. H.</given-names></name><name><surname>Toh</surname><given-names>M. L.</given-names></name><name><surname>Clyne</surname><given-names>C. D.</given-names></name><name><surname>Leech</surname><given-names>M.</given-names></name><name><surname>Aeberli</surname><given-names>D.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>177</volume>
<fpage>8148</fpage>&#x02013;<lpage>8153</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.177.11.8148</pub-id>
<?supplied-pmid 17114490?><pub-id pub-id-type="pmid">17114490</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Effect of vaccine administration modality on immunogenicity and efficacy.</article-title>
<source><italic>Expert Rev. Vaccines</italic></source>
<volume>14</volume>
<fpage>1509</fpage>&#x02013;<lpage>1523</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2015.1081067</pub-id>
<?supplied-pmid 26313239?><pub-id pub-id-type="pmid">26313239</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Xia</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Annexin A1 translocates to nucleus and promotes the expression of pro-inflammatory cytokines in a PKC-dependent manner after OGD/R.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>6</volume>:<issue>27028</issue>. <pub-id pub-id-type="doi">10.1038/srep27028</pub-id>
<?supplied-pmid 27426034?><pub-id pub-id-type="pmid">27426034</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhirnov</surname><given-names>O. P.</given-names></name><name><surname>Klenk</surname><given-names>H. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling.</article-title>
<source><italic>Apoptosis</italic></source>
<volume>12</volume>
<fpage>1419</fpage>&#x02013;<lpage>1432</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-007-0071-y</pub-id>
<?supplied-pmid 17468837?><pub-id pub-id-type="pmid">17468837</pub-id></mixed-citation></ref></ref-list></back></article>